Intelligence · Clinical Pipeline
Nektar Therapeutics UK Pipeline
All ClinicalTrials.gov programs at Nektar Therapeutics UK — phase, modality, and trial IDs.
- Programs
- 14
Quick answer
Nektar Therapeutics UK has 14 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
145 mg/m2 NKTR 102
Nektar Therapeutics UK Limited
Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment
1 trial -
Bempegaldesleukin
Nektar Therapeutics UK Limited
Covid-19
1 trial -
Bempegaldesleukin (NKTR-214)
Nektar Therapeutics UK Limited
Metastatic Melanoma
1 trial -
C-TIL051
Nektar Therapeutics UK Limited
Metastatic Non Small Cell Lung Cancer
1 trial -
Cyclophosphamide
Nektar Therapeutics UK Limited
Recurrent Diffuse Large B-Cell Lymphoma
1 trial -
LY3471851
Nektar Therapeutics UK Limited
Dermatitis, Atopic
1 trial -
LY3471851
Nektar Therapeutics UK Limited
Healthy
4 trials -
NKTR-102
Nektar Therapeutics UK Limited
Advanced Cancer
1 trial -
NKTR-181
Nektar Therapeutics UK Limited
Moderate to Severe Chronic Pain
1 trial -
NKTR-214
Nektar Therapeutics UK Limited
Advanced Cancer
1 trial -
NKTR-255
Nektar Therapeutics UK Limited
Multiple Myeloma
1 trial -
Nivolumab
Nektar Therapeutics UK Limited
Renal Cell Carcinoma
1 trial -
Placebo
Nektar Therapeutics UK Limited
Psoriasis
1 trial -
TAK-659
Nektar Therapeutics UK Limited
Lymphoma, Non-Hodgkin
1 trial
Frequently asked questions
How many pipeline programs does Nektar Therapeutics UK have?
14 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs